(Q33504893)

27 July 2017

title

Response to gefitinib and erlotinib in Non-small cell lung cancer: a restrospective study (English)

1 reference

27 July 2017

Ivette F Emery

1

1 reference

27 July 2017

Chiara Battelli

2

1 reference

27 July 2017

Paul L Auclair

3

1 reference

27 July 2017

Kathleen Carrier

4

1 reference

27 July 2017

Daniel M Hayes

5

1 reference

27 July 2017

language of work or name

English

0 references

publication date

18 September 2009

1 reference

27 July 2017

1 reference

27 July 2017

volume

9

1 reference

27 July 2017

page(s)

333

1 reference

Creative Commons Attribution 2.0 Generic

27 July 2017

copyright license

start time

18 September 2009

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

High predictive value of epidermal growth factor receptor phosphorylation but not of EGFRvIII mutation in resected stage I non-small cell lung cancer (NSCLC)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758901

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758901

Erlotinib in previously treated non-small-cell lung cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758901

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758901

Phosphorylation state-specific antibodies: applications in investigative and diagnostic pathology

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758901

Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758901

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758901

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

21 June 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-333

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-333

Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-333

Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-333

Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758901

Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage

31 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19765296

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19765296

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19765296

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/1471-2407-9-333

1 reference

Dimensions Publication ID

27 July 2017

0 references

1 reference

27 July 2017

1 reference